Evercore ISI Lowers Health Catalyst (NASDAQ:HCAT) Price Target to $8.00

Health Catalyst (NASDAQ:HCAT) had its price target decreased by equities research analysts at Evercore ISI from $9.00 to $8.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Evercore ISI’s target price points to a potential upside of 36.52% from the stock’s current price.

Other analysts also recently issued reports about the company. Canaccord Genuity Group reissued a “buy” rating and issued a $11.00 target price on shares of Health Catalyst in a research report on Tuesday, May 21st. KeyCorp reissued a “sector weight” rating on shares of Health Catalyst in a research report on Wednesday, April 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research report on Wednesday, April 10th. Piper Sandler decreased their target price on Health Catalyst from $15.00 to $14.00 and set an “overweight” rating for the company in a research report on Thursday, June 6th. Finally, Wells Fargo & Company decreased their target price on Health Catalyst from $14.00 to $13.00 and set an “overweight” rating for the company in a research report on Friday, May 10th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.91.

Health Catalyst Stock Performance

Shares of NASDAQ:HCAT opened at $5.86 on Tuesday. The business’s 50 day simple moving average is $6.49 and its two-hundred day simple moving average is $7.75. The firm has a market cap of $345.95 million, a P/E ratio of -3.17 and a beta of 1.32. Health Catalyst has a 52-week low of $5.45 and a 52-week high of $14.37.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. Health Catalyst had a negative return on equity of 11.86% and a negative net margin of 35.56%. The business had revenue of $74.72 million for the quarter, compared to analyst estimates of $74.81 million. On average, equities analysts forecast that Health Catalyst will post -0.4 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Daniel Lesueur sold 5,208 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $6.15, for a total value of $32,029.20. Following the completion of the sale, the chief operating officer now owns 155,215 shares of the company’s stock, valued at approximately $954,572.25. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 9,279 shares of company stock valued at $58,742. Insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Health Catalyst by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 6,441,707 shares of the company’s stock valued at $65,190,000 after purchasing an additional 78,823 shares during the period. Impax Asset Management Group plc increased its holdings in Health Catalyst by 52.0% during the 4th quarter. Impax Asset Management Group plc now owns 1,754,475 shares of the company’s stock valued at $16,246,000 after purchasing an additional 600,000 shares during the period. Primecap Management Co. CA increased its holdings in Health Catalyst by 26.7% during the 4th quarter. Primecap Management Co. CA now owns 1,419,577 shares of the company’s stock valued at $13,145,000 after purchasing an additional 299,139 shares during the period. Kennedy Capital Management LLC purchased a new position in Health Catalyst during the 1st quarter valued at about $8,780,000. Finally, Nepsis Inc. increased its holdings in Health Catalyst by 6.0% during the 1st quarter. Nepsis Inc. now owns 1,157,394 shares of the company’s stock valued at $8,715,000 after purchasing an additional 65,462 shares during the period. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.